<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848637</url>
  </required_header>
  <id_info>
    <org_study_id>192BE18036</org_study_id>
    <nct_id>NCT03848637</nct_id>
  </id_info>
  <brief_title>The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 2-period, 2-treatment, Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of CKD-375 Tablet With D387 Tablet in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the pharmacokinetics and
      safety/tolerability after oral administration of CKD-375 and D387 in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 14, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration of Empagliflozin</measure>
    <time_frame>Time Frame: 0 hour ~ 48 hour after drug administration</time_frame>
    <description>Cmax of Empagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration of Metformin</measure>
    <time_frame>Time Frame: 0 hour ~ 48 hour after drug administration</time_frame>
    <description>Cmax of Metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration of Empagliflozin-time curve from time zero to time of last measurable concentration</measure>
    <time_frame>Time Frame: 0 hour ~ 48 hour after drug administration</time_frame>
    <description>AUClast of Empagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration</measure>
    <time_frame>Time Frame: 0 hour ~ 48 hour after drug administration</time_frame>
    <description>AUClast of Metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration of Empagliflozin-time curve from time zero to infinity</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>AUCinf of Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration of Metformin-time curve from time zero to infinity</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>AUCinf of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum (peak) plasma concentration of Empagliflozin following drug administration</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Tmax of Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum (peak) plasma concentration of Metformin following drug administration</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Tmax of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>t1/2 of Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>t1/2 of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>CL/F of Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>CL/F of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Vd/F of Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of Metformin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Vd/F of Metformin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D387 (reference drug)
Period 2: CKD-387 (test drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-387 (test drug)
Period 2: D387 (reference drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-375</intervention_name>
    <description>Test drug</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D387</intervention_name>
    <description>Reference drug</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults aged 19 to 55 years

          2. Females who are not pregnant or breastfeeding or who have surgical infertility

          3. Signed informed consent form

          4. Other inclusion criteria, as defined in the protocol

        Exclusion Criteria:

          1. History of clinically significant hepatic, renal, nervous, immune, respiratory,
             endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder

          2. Clinical laboratory test values are outside the accepted normal range at Screening

          3. Current smokers or those who cannot quit smoking during the period from 90 days before
             the first IP dosing to the last discharge.

          4. Subject who drink excessive caffeine or alcohol continuously and who cannot
             discontinue caffeine or alcohol intake during the period from 3 days before the first
             IP dosing to the last discharge.

          5. Participated in a clinical trial within 90 days prior to 1st IP dosing

          6. Not eligible to participate for the study at the discretion of Investigator

          7. Other exclusive inclusion criteria, as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung-Sang Yu, M.D.,Ph.D</last_name>
    <phone>+82-2-2072-1920</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soyoung Lee, Pharmacist</last_name>
    <phone>+82-2-740-8872</phone>
    <email>sylee0829@snu.ac.kr</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

